Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Income (2022 - 2025)

Historic Net Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' Net Income fell 14458.34% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 5004.46%. This contributed to the annual value of $8.0 million for FY2024, which is 11471.17% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Net Income of -$53.2 million as of Q3 2025, which was down 14458.34% from -$47.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Net Income's 5-year high stood at $47.2 million during Q4 2024, with a 5-year trough of -$53.2 million in Q3 2025.
  • Over the past 4 years, ARS Pharmaceuticals' median Net Income value was -$15.4 million (recorded in 2022), while the average stood at -$16.3 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' Net Income plummeted by 22476.36% in 2023 and then soared by 56153.92% in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Net Income stood at -$15.4 million in 2022, then soared by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then plummeted by 212.7% to -$53.2 million in 2025.
  • Its Net Income was -$53.2 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$37.2 million in Q1 2025.